{"text": "2.T2DM合并心血管系统疾病：T2DM合并心血管系统疾病患者PPG较高时可选用α-糖苷酶印制剂、DPP-4抑制剂、格列奈类或短效促泌剂。MeRIA研究证实了阿卡波糖的治疗与T2DM患者的心血管预后改善相关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管系统疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶印制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列奈类", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "短效促泌剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管系统疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，对于临床诊断为2型糖尿病的所有患儿，也应考虑糖尿病自身抗体检测。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、糖尿病足及高危足的概念 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "高危足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.糖尿病合并心血管高危因素患者", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利司那肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "儿童期肥胖容易伴随焦虑、自卑等心理问题，同时也是成人肥胖、糖尿病、心血管疾病及其他代谢性疾病和肿病的潜在危险因素。医学营养治疗主要通过培养良好的生活习惯而达到控制体重的目的。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "UKPDS研究中患者糖尿病史较短，血糖控制尤其早期控制更为重要；而VADT、ACCORD和ADVANCE研究中患者病史相对较长。所以对于糖尿病病程较短，无并发症的患者，强化血糖控制可带来更多的血管并发症获益；而对于病史较长，合并症较多的患者，强化血糖控制并不能带来更多的心血管获益。糖尿病治疗的目的要兼顾用心血管获益和用药安全，合并CVD的糖尿病患者，一旦发生低血糖可诱发心肌梗死及卒中等，因而对于这类人群应尽量在避免低血糖的情况下使血糖控制达标。综合循证医学研究结果，并充分平衡风险和血管获益，结合患者的年龄、糖尿病病程以及CVD病史等，将血糖控制目标个体化。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "院内高血糖是指血糖水平>7.8mmol/L，若血糖水平持续而明显地高于此水平则提示患者有可能需要接受治疗。造成高血糖的原因既可以是由于已知的或未诊断的糖尿病，也可以是由于急危重症所致的应激性高血糖。不论高血糖的原因如何，也不论患者是否伴有糖尿病，高血糖均会增加住院患者的并发症和死亡风险。对所有的高血糖患者在入院时均应检测血糖并应询问是否有糖尿病病史，必要时检测HbA1c水平以明确患者住院前是否已经存在糖尿病。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖水平", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病发展至胰岛素分泌不足阶段，需要联合胰岛素促分泌剂、必要时联合基础胰岛素，多重机制降血糖(A)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促分泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌不足", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、糖尿病周围神经病的诊断标准", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "急性失代偿性心衰患者使用襻利尿剂或合并慢性肾衰竭等都可能引起血尿酸升高，导致不良预后，去除这些混杂因素后，高尿酸仍与短期预后不良(院内死亡)和长期预后不良(心源性死亡和心衰再次入院)相关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "急性失代偿性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "襻利尿剂", "subject_type": "药品名称", "object": {"@value": "急性失代偿性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)如年轻的新诊断糖尿病患者和低血糖低危人群，在接受内科治疗的同时需严格控制血糖；其他内科疾病患者，若是高龄、或无法耐受低血糖、或存在器官功能不全，或预期寿命<5年、存在精神或智力障碍、本身是心脑血管疾病患者或心脑血管疾病高危人群,仅需宽松或一般控制血糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "e.利格列汀治疗的临床研究中报告的其他不良反应有高敏反应(例如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "高敏反应", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "荨麻疹", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "局部皮肤剥脱", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "支气管高敏反应", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "7.糖尿病并发症的筛查与防治(自我管理处方)：(1)预防和延缓并发症：对于尚未确诊糖尿病并发症的患者，自我管理处方需要包含预防和延缓尿病并发症的实用措施，如：糖尿病急慢性并发定的识别、糖尿病并发症筛查表(包括检查的项目、时间、频率、意义等)、并发症的预防措施等；(2)并发症的自我管理与日常保健：对于已经患有糖尿病并发症的患者，根据患者的并发症类型提供自我管里处方，包括定期复查(包括复查项目、复查频次、在哪里复查、复查前注意事项等)、自我保健(如糖尿病足的日常护理、皮肤护理、牙齿护理等)、注意事项(如糖尿病肾病患者需要注意蛋白质的摄取、糖尿病视网膜病变的患者需要注意运动的强度等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "自我管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "日常保健", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自我保健", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "日常护理", "subject_type": "非药治疗", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "皮肤护理", "subject_type": "非药治疗", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "牙齿护理", "subject_type": "非药治疗", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "b.维格列汀和沙格列汀在对猴子进行的毒理学研究中，出现四肢皮肤的损伤报告，尽管未在临床中观察到皮肤损伤的发生率升高，但在合并有糖尿病皮肤并发症的患者中经验有限。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "糖尿病皮肤并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "四肢皮肤的损伤", "subject_type": "不良反应", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮肤损伤", "subject_type": "不良反应", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "糖尿病皮肤并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "四肢皮肤的损伤", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮肤损伤", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "皮肤", "subject_type": "患病部位", "object": {"@value": "糖尿病皮肤并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "多因肢端循环及微循环障碍，常伴周围神经病变和患足感染。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "患足感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年糖尿病患者可分为老年前患糖尿病和老年后新发糖尿病两种情况。两者在自身状况、糖尿病临床特点、罹患其他疾病和已存在的脏器功能损伤等方面均有所不同。在环境因素相似的情况下，患病越晚提示胰岛β细胞代偿能力越好。与进入老年前已患病者比较，老年后患糖尿病者更多表现为明显胰岛素抵抗和胰岛素代偿性高分泌。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脏器", "subject_type": "患病部位", "object": {"@value": "脏器功能损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素代偿性高分泌", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "积极控制血糖、血压、血脂等危险因素是预防和延缓糖尿病微血管并发症的基础，基本原则包括纠正高血糖、高血压及血脂异常。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "六、T2DM合并肥胖心血管风险因素的控制", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.低血糖的治疗和预防：参见本章节”(一)内分泌科住院糖尿病患者的血糖管理”中“2.内分泌科住院糖尿病患者的血糖管理”中对低血糖的管理。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "自我管理处方是一种个体化的糖尿病教育管理工具，将2型糖尿病全方位自我管理的知识和技能以处方形式综合为一体，且随着处方的实施和不断改进，能将DSME/S延续并形成持续支持的糖尿病教育管理行为改变闭环。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自我管理", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.慢性肾病(CKD)1~5期患者", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病(CKD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7. 吸烟或被动吸烟增加HUA和痛风的发病风险，应当戒烟、避免被动吸烟。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "吸烟", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "吸烟", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "被动吸烟", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "被动吸烟", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免被动吸烟", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免被动吸烟", "subject_type": "非药治疗", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.胰岛素促泌剂的禁忌证：药物过敏、1型糖尿病、糖尿病酮症酸中毒、高糖性高渗透压综合征、严重肝或肾损伤和哺乳期患者等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "严重肝或肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "严重肝或肾损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病的教育管理涉及多学科知识.需要采取综合性措施，因而自我管理处方需要囊括多方面内容，包括综合评估、个性化控制目标、情绪管理、自我监测、饮食管理、运动管理、用药管理、胰岛素注射技术、糖尿病并发症筛查以及卫生资源支持。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "教育管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "有研究表明T2DM患者的肿瘤风险增加，甚至某些回顾性的资料分析发现磺脲类药物可能增加肿瘤的风险，但高水平高级别的证据如从UKPDS到近期发表的ADVANCE亚组分析均未发现磺脲类药物增加患者肿瘤风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "根据我国住院患者病情轻者比例较高，新诊断糖尿病患者入院治疗较多，住院期间新发现的糖尿病患者较多，住院患者病情差异性大等特点，推荐我国住院血糖管理分为以下3种：(1)科室自我管理模式：(2)会诊专业管理模式；(3)互联网系统管理模式。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "11.二甲双胍联合GLP-1受体激动剂的疗效：目前，中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG和HbA1c，提高血糖达标率，改善胰岛β细胞功能，改善IR，降低体重和SBP，且不增加严重低血糖发生的风险(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍降糖疗效相当，前者使体重和血压降低，低血糖发生风险减少。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "严重低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "a.西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整；尚无严重肝功能不全患者使用的临床经验。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "美国药品食品监督管理局(FDA)批准达格列净、卡格列净和恩格列净的起始剂量分别为5mg、100mg和10mg，根据血糖控制的需求和是否耐受可调整至最大剂量10mg、300mg和25mg，每日一次口服，达格列净和思格列净餐前或餐后均可服用，坎格列净需要在第一次正餐前口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10mg，对于重度肝功能不全的患者可从5mg起始。美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT2i可单独使用及与其他降糖药物联合使用。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "5mg", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10mg", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg", "subject_type": "用药剂量", "object": {"@value": "卡格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "300mg", "subject_type": "用药剂量", "object": {"@value": "卡格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "卡格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10mg", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25mg", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "坎格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "5mg", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10mg", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "建议GLP-1RA用于超重/fie胖2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)病情监测与控制目标：血糖控制不良或不稳定时，应每日监测全天血糖谱(三餐前后、睡前血糖)，必要时可进行CGMS。当孕妇出现不明原因恶心、呕吐、乏力等不适或者血糖控制不理想时还应及时监测尿酮体，必要时行血气分析。妊娠期间血糖控制目标根据糖尿病类型不同有所不同(表4)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "根据流行病学资料，既往HUA定义为正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol／L，女性>360 μmol／L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血尿酸水平", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.二甲双胍在治疗PCOS方面的作用：国内外应用二甲双胍治疗PCOS已有10余年的历史。美国内分泌学会推荐，二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。AACE/ACE PCOS临床诊治指南中推荐二甲双胍可作为青少年女性PCOS单药或联合避孕药和抗雄激素药治疗的一线用药。在偏瘦的青少年女性中，最低日剂量控制在850mg可有效改善PCOS症状；在超重和肥胖的青少年女性中，二甲双胍日治疗剂量常需要增至1500~2500mg(V级)。同时，该指南中提到，二甲双胍可减轻绝经前PCOS妇女的MS相关症状。循证医学证据表明，二甲双胍可降低血浆胰岛素水平、增加IS、降低雄激素水平、提高雌二醇(E2)水平，改善PCOS患者的多毛症，使月经规律、诱导排卵。同时，二甲双胍用于PCOS患者除改善IR和高血糖症等代谢状况外，还被证明可改善PCOS患者的排卵、受孕及生产存活率。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "避孕药", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "抗雄激素药", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1500~2500mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "MS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆胰岛素", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "雄激素", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "雌二醇(E2)", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "多毛症", "subject_type": "临床表现", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "高血糖症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.一线药物治疗：许多国家和国际组织制定的糖尿病指南推荐：若无禁忌且能耐受，二甲双胍是2型糖尿病患者的基础用药。UKPDS还显示二甲双胍可减少超重或肥胖2型糖尿病患者的心血管事件和死亡。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "荟萃分析表明，与安慰剂相比，前列腺素El(PGE I) 能够显著增加步行距离，即使停止治疗后其步行能力仍然保持增加。脂微球前列地尔注射液的剂量根据患者病变程度推荐为10μg/次，1~2次/d，静脉推注或滴注，疗程14~ 21d。贝前列素钠治疗能改善糖尿病性周围血管病变患者下肢的主观症状，如烧灼样感觉、冷感觉、水肿、劳力性疼痛、针刺样疼痛及感觉异常。与安慰剂相比，每日口服贝前列素钠40μg，3次/d，治疗6个月，无痛性行走距离改善超过50%的LEAD患者在两组分别为43.5%与33.3%，两组间无痛性行走距离分别增加81.5%和52.5%，最大步行距离分别增加60.1%和35.0%，严重心血管事件的发生率分别为4.8%和8.9%。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "1~2次/d", "subject_type": "用药频率", "object": {"@value": "脂微球前列地尔注射液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "14~ 21d", "subject_type": "持续时间", "object": {"@value": "脂微球前列地尔注射液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10μg/次", "subject_type": "用药剂量", "object": {"@value": "脂微球前列地尔注射液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉推注或滴注", "subject_type": "用药方法", "object": {"@value": "脂微球前列地尔注射液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "烧灼样感觉", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "冷感觉", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "水肿", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "劳力性疼痛", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "针刺样疼痛", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "糖尿病性周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "LEAD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "6个月", "subject_type": "持续时间", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "3次/d", "subject_type": "用药频率", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "40μg", "subject_type": "用药剂量", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}]}
{"text": "在中国新诊断2型糖尿病患者中，胰岛素抵抗为主、胰岛素分泌缺陷为主以及胰岛素分泌缺陷伴胰岛素抵抗的患者各占约1/3(2c级)。对中国新诊断2型糖尿病患者的调查发现，随着空腹血糖水平增高，患者胰岛素分泌功能的下降较胰岛素敏感性降低更明显，且非肥胖(体重指数<24kg/m2)的2型糖尿病患者胰岛素分泌功能更差(2c级)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌缺陷", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌缺陷", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "空腹血糖水平增高", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌功能的下降较胰岛素敏感性降低更明显", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌功能更差", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.他汀类药物本身可引起肝功能受损，主要表现为转氨酵升高，发生率约0.5%~3.0%，常见于开始用药或增大剂量的12周内，且呈剂量依赖性，极少引起肝衰竭；当血清ALT或AST<2.5xULN，同时TBil正常，可观察，无需调整剂量；如血清ALT或AST2.5~3.0xULN时可减量；如血清ALT或AST≥3.0xULN时应停药：当ALT恢复正常时.可酌情再次加量或换药。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肝功能受损", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝衰竭", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "12周", "subject_type": "持续时间", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(一)T2DM合并肝病或肝功能异常", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.出现影响自我管理新的复杂因素时：指出现新的健康状况如肾脏疾病、卒中及需要复杂药物：出现身体机能受限如视力受损、移动受限；出现情感因素如焦虑和抑郁；出现基本生活需求如食物获取和经济能力有限时。需要及时调整自我管理处方，调整内容包括：个性化的行为改变及健康应对的策略、增加所需要的特殊自我护理技能，以延缓糖尿病并发症进展及预防新的并发症发生，必要时提供和抑郁相关的情感支持。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "视力受损", "subject_type": "临床表现", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "移动受限", "subject_type": "临床表现", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "视力受损", "subject_type": "临床表现", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "移动受限", "subject_type": "临床表现", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "提供和抑郁相关的情感支持", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "增加所需要的特殊自我护理技能", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素抵抗和β细胞胰岛素分泌缺陷是2型糖尿病发病的两大因素，胰岛素抵抗常常是2型糖尿病发生的始动因素，但如果β细胞胰岛素分泌功能保持其代偿能力，2型糖尿病并不会发生，因此，β细胞胰岛素分泌功能缺陷是2型糖尿病发病病的中心环节之一(5级)。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌缺陷", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "胰岛素抵抗", "subject_type": "患病病因", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌功能缺陷", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性肾脏病(chronic kidney disease，CKD)已成为全球性重要公共卫生问题，中国流行病学研究显示，我国普通人群CKD的患病率为10.8%，中国南方地区普通人群为12.1%，农村地区为13.6%，高原地区藏族人群为19.1%，北方地区普通人群为16.9%。CKD持续进展至终末期肾病(end stage renal disease，ESRD)会严重影响患者的生存和生活质量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(chronic kidney disease，CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病(end stage renal disease，ESRD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病(end stage renal disease，ESRD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖异常增高是围术期的常见问题。一方面，手术创伤应激诱发机体分泌儿茶酚胺、皮质醇和炎性介质等胰岛素拮抗因子，促使血糖增高。另一方面，合并糖尿病、代谢综合征等胰岛素抵抗或胰岛素分泌障碍疾病的患者更容易发生围术期高血糖。另外，围术期经常使用的激素、含糖营养液等进一步增加了高血糖的风险。值得注意的是，长时间禁食和不恰当的降糖治疗也有引起患者低血糖和血糖剧烈波动的可能。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "围术期", "subject_type": "分期分型", "object": {"@value": "围术期高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "激素", "subject_type": "患病病因", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "含糖营养液", "subject_type": "患病病因", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长时间禁食", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不恰当的降糖治疗", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)伴心血管疾病或心血管风险高的患者", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "药物经济学已经成为评价临床治疗方案的重要手段之一。在选择2型糖尿病治疗方案时，应综合考虑控制医疗费用、患者病情及其支付能力等多方面因素。作为发展中国家，我国医疗资源仍相对匮乏，且糖尿病患者人数众多且增长迅猛，在为2型糖尿病制定胰岛素治疗方案时需考虑以上诸多因素。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "瑞格列奈、利格列汀在肾功能不全时无需调整剂量；二甲双胍在GFR45~59ml·min-1·1.73m-2时应减量，GFR<45ml·min-1·1.73m-2禁用；α-糖苷酶抑制剂在GFR<30ml·min-1·1.73m-2时禁用。其他药物在肾功能不全中的应用详见图2。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素@(4)对于非急危重症患者，可考虑皮下胰岛素注射。胰岛素注射剂量根据进餐和睡眠时间进行设定；如未进食或有持续肠内或肠外营养，每4~6h皮下注射短效或速效胰岛素。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下胰岛素注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "13.应尽早足量使用以维持更长的达标时间：在500~2000mg剂量范围，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本效益比(Ⅰ级)。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500~2000mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "痛风患者最常见表现为痛风性关节炎，但长期HUA可引起和／或加重其他多器官损伤，并发肾脏肾病变（急性尿酸性肾病、慢性尿酸盐肾病、肾石症)、高血糖、血脂紊乱，高血压、冠心病、心功能不全及卒中等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏肾病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾脏肾病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②血糖控制差且非急危重症：(a)第1类患者糖代谢紊乱严重，尚未危及生命，但持续高血糖状态可促使病情进展，应积极逆转，是胰岛素治疗的指征。降糖治疗需应用胰岛素，可相对短的时间静脉输注改善高糖毒性，缓解临床症状后改皮下注射。与前述“①合并急危重症者”中“(a)合并急性并发症“部分静脉胰岛素使用原则相同，不同的是开始时胰岛素剂量0.05U·kg-1·d-1，且静脉滴注时间相对短。患者血糖稳定在8.0~11.1mmol/L后2~4h，可改为多次胰岛素(基础一餐时)皮下注射或胰岛素泵治疗。同时改每小时监测血糖为每天检测7次血糖或4~6个监测点，必要时加测夜间血糖。依据血糖调整胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案。(b)第2、3类患者均为胰岛素治疗的指征。降糖治疗亦应用胰岛素，最好采用胰岛素强化治疗方案，包括：基础加餐时胰岛素的MDI、CSⅡ、预混胰岛素类似物每日3次皮下注射，优选前两种。胰岛素强化治疗时，胰岛素起始剂量选择可按0.4~0.5U·kg-1·d-1。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。监测7次血糖，必要时加测夜间血糖。依据血糖调整胰岛素用量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案根据病情可选择加用或不加用口服降糖药及胰升糖素样肽1(GLP-1)受体激动剂。需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，以及评估患者的估算肾小球滤过率(eGFR)。二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。因采用胰岛素强化治疗方案，原则上不联用胰岛素促泌剂。(c)第4类患者相对病情轻。对于胰岛素缺乏为主的患者仍应胰岛素治疗，可以基础胰岛素联合口服降糖药治疗，或预混胰岛素2次皮下注射，必要时也可胰岛素强化治疗。每天1次基础或预混胰岛素注射时，胰岛素起始剂量选择0.2U·kg-1·d-1。每天2次预混胰岛素注射时，胰岛素起始剂量选择可按0.2~0.4U·kg-1·d-1，按照1：1比例分配于早晚餐前。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。与前述相同，需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，要估算eGFR。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "持续高血糖状态", "subject_type": "临床表现", "object": {"@value": "糖代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.05U·kg-1·d-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉滴注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "MDI", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "CSⅡ", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.4~0.5U·kg-1·d-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每天1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2U·kg-1·d-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每天2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2~0.4U·kg-1·d-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.推动实施生命全周期的健康管理。开展孕期和分娩后体重管理和血糖筛查，推动母乳喂养和正确添加辅食。培养儿童、青少年的健康行为和技能，保证学生在校每天1小时运动，预防儿童青少年肥胖。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "每天1小时运动", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "诊断早期或病情较轻的2型糖尿病患者可能1种降糖药即可控制血糖，但由于2型糖尿病是进展性疾病，随病程延长需要2种以上不同种类的降糖药联用。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "60.0%-71.0%的阿格列汀以原型通过尿液排泄。轻度肾功能受损患者中，阿格列汀的血浆AUC升高程度不具有临床相关性。中度肾功能受损患者中阿格列汀的血浆AUC约升高2倍。重度肾功能受损和终末期肾病患者中，阿格列汀的血浆AUC分别约升高3倍和4倍，透析3h可清除体内7.0%的药物。因此中重度糖尿病合并慢性肾脏病患者应谨慎用药。大部分(约90.0%)的利格列汀以原型排泄，肾排泄低于给药剂量的5.0%，因此此药的使用不受肾功能降低的影响。利格列汀用于慢性肾脏病1~5期的患者时无需调整剂量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "同时还可以显著提高下肢动脉病变患者的运动功能指标，如行走受损问卷(WIQ) 距离评分、WIQ速度评分、WIQ爬梯评分。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.口服降糖药物未达标加用或改用胰岛素的患者，其血糖控制目标值可适当放宽至HbA1c<7%，以减少低血糖和体重增加这两大不良反应。Miller等对1055例2型糖尿病患者(平均年龄61岁，病程10.8年)的低血糖发生情况调查显示，在随访的7个月中有24.5%的患者至少发生过一次低血糖(有低血糖症状并且血糖<3.3mmol/L)，其中生活方式干预组(HbA1c<6%)占11.8%，口服药物治疗组(HbA1c<7%)占16.2%，胰岛素治疗组(HbA1c<8.1%)占30.5%，而且随访过程中发生的5例严重低血糖事件(0.5%)均在胰岛素治疗组。UKPDS和ACCORD均发现胰岛素使体重增加，若体重增加，可能加重胰岛素抵抗，增加CVD风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重低血糖事件", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "体重增加", "subject_type": "患病病因", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)一般在口服降糖药治疗的基础上加用预混胰岛素类似物每日1次治疗，临床医生也可根据患者具体情况调整口服降糖药；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于特定人群(3期或3期以上CKD的朝鲜人、所有中国汉族和泰国人)，其HLA-B*5801等位基因频率较高，HLA-B*5801阳性个体发生严重别嘌醇超敏反应危险性极高。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "3期或3期以上", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}]}
{"text": "DSME/S是促进糖尿病自我保健知识、技能和能力的一个持续性过程。2015年发表的联合立场声明中强调了评估、实施、调整DSME/S的4个关键时机，包括：确诊时、年度教育、出现影响自我管理新的复杂影响因素时、管理方案发生改变时。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "DSME/S", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床上应用的胰岛素制剂历经两次换代，即动物胰岛素-人胰岛素-胰岛素类似物，更新换代的目的就是希望能够更好地模拟生理性胰岛素分泌，以速效胰岛素类似物为例，其与短效人胰岛素同为模拟餐时胰岛素分泌，但在控制血糖和减少低血糖风险等方面均优于后者，而且可以餐前即刻注射更为方便，能够提高患者的治疗依从性。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "餐前即刻注射", "subject_type": "用药方法", "object": {"@value": "短效人胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "6.联合磺脲类药物的疗效：二甲双胍可改善IR，降低肝糖输出，磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM的病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c。针对磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时可更好地控制FPG(Ⅰ级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降幅(1.7%)显著高于二甲双胍联合阿卡波糖治疗组的HbA1c降幅(0.9%)，且两组间低血糖、体重增加无差异无统计学意义。另有随机、双盲、双模拟、平行对照研究显示，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂与相同剂量的格列本脲相比，降糖效果相当，但低血糖发生的风险显著减低。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.噻唑烷二酮类：常用药物有罗格列酮和吡格列酮。每日早餐前1次服用。主要通过改善外周组织胰岛素抵抗而降低血糖。噻唑烷二酮类药物可以使HbA1c下降1.0%~1.5%。噻唑烷二酮类药物单独使用时不导致低血糖。但体重增加和水肿是其常见副作用。临床研究发现噻唑烷二酮类药物与骨折和心力衰竭风险增加相关。有心力衰竭[纽约心脏病协会(NYHA)心功能Ⅱ级以上]的患者、活动性肝病或转氨酶增高超过正常上限2.5倍的患者，以及有严重骨质疏松和骨折病史的患者，应禁用本类药物。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "骨折", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心力衰竭风险增加", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "活动性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "活动性", "subject_type": "分期分型", "object": {"@value": "活动性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨质", "subject_type": "患病部位", "object": {"@value": "骨质疏松"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅱ级以上", "subject_type": "分期分型", "object": {"@value": "纽约心脏病协会(NYHA)心功能Ⅱ级以上"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "14.用于正在接受胰岛素治疗的T1DM患者：对于T1DM患者可联用二甲双胍。临床研究发现其不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C；对于单用胰岛索治疗血糖控不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。中国T1DM诊治指南也支持T1DM在使用胰岛素治疗的前提下联用二甲双胍。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重过度增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.碱化尿液治疗：接受降尿酸药物，尤其是促尿酸排泄药物治疗的患者及尿酸性肾石症患者，推荐将尿PH值维持在6.2—6.9，以增加尿中尿酸溶解度。尿pH值过高增加磷酸钙和碳酸钙等结石形成风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿pH值过高", "subject_type": "患病病因", "object": {"@value": "结石形成"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)抗凝治疗：糖尿病下肢缺血患者，多为血液高凝状态，可以采用抗凝措施防止血栓形成，尤其是在膝下动脉血运重建后。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "下肢缺血", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列酮可有效降低尿白蛋白排率泄，并能够抑制NF-κB及其下游炎症因子的激活，抑制糖基化终产物诱导的人肾系膜细胞RANTES的表达和分泌，从而减缓糖尿病肾病的发生发展.。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "无痛风发作病史的HUA患者接受降尿酸治疗时不推荐使用预防痛风发作药物，但应告知有诱发痛风发作的风险。一旦发生急性痛风性关节炎，应及时治疗，并考虑后续预防用药的必要性。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "急性痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在上述背景下，加之膳食结构变化后肠道菌群结构发生的适应性变化，使得这类具有遗传易感性者对三大宏量营养素(碳水化合物、蛋白质、脂肪)的应答出现显著差异，进面造成肥胖的发生。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "膳食结构变化后肠道菌群结构发生的适应性变化", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "遗传易感性", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "三大宏量营养素(碳水化合物、蛋白质、脂肪)的应答出现显著差异", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "特别提到使用过程中需注意药物不良反应，强调亚裔人群使用别嘌呤醇时发生严重超敏反应的风险明显高于白种人。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "嘌呤醇"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.作用于心血管系统，降低收缩压、改善心肌缺血和心肌收缩功能。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌缺血"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "12.二甲双胍联合胰岛素的疗效：二甲双胍可以增强肝脏和肌肉组织的IS，口服降糖药联合治疗血糖控制不佳的T2DM患者启动胰岛素治疗后应保留二甲双胍。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险，联合使用还可能与心血管疾病和肿瘤风险下降相关(I级)。HOME研究是一项前瞻性、随机、双盲、安慰剂对照研究，该研究对接受胰岛素治疗的T2DM患者随访4.3年。结果显示，较单纯胰岛素治疗，二甲双胍联合胰岛素治疗能提高降糖疗效，降低胰岛素用量(胰岛素日剂量平均减少19.63U)，且体重增加更少。对该研究的次级终点的分析显示，二甲双胍的治疗与大血管事件相对风险降低40%相关(I级)。一项随机、对照研究纳入96例磺脲类继发性失效的T2DM患者，治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组均有所增加；且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大、每日胰岛素用量最少、低血糖的发生率最低。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "4.3年", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "19.63U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年糖尿病患者常合并其他代谢异常，在综合评估治疗风险的基础上，应根据老年糖尿病的特点，选择合适的血压、血脂、血尿酸及体重的控制目标。老年糖尿病患者常为多病共存，需要服用多种治疗药物。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "枸橼酸盐是尿中最强的内源性结石形成抑制物，同时可碱化尿液，增加尿尿酸溶解度，溶解尿酸结石并防止新结石的形成。枸橼酸氢钾钠起始剂量2.5～5.0g／d，服用期间需监测尿pH值以调整剂量。急性肾损伤或慢性肾衰竭(G4~5期)、严重酸-碱平衡功能失调及肝功能不全患者禁用。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "2.5～5.0g／d", "subject_type": "用药剂量", "object": {"@value": "枸橼酸氢钾钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G4~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.大量饮水可缩短痛风发作的持续时间，心肾功能正常者需维持适当的体内水分，多饮水，维持每日尿量2000～3000ml。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "大量饮水", "subject_type": "非药治疗", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病微循环障碍临床用药专家共识", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)血脂紊乱：血脂紊乱是HUA和痛风常见的合并症，高甘油三酯血症是发生HUA的独立预测因素。对于高胆固醇血症或动脉粥样硬化合并HUA患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先考虑非诺贝特。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "附录提供了2型糖尿病生活方式自我管理处方和胰岛素使用自我管理处方范例。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.DKA：在SGLT2i临床研究中及上市后临床应用中，曾发现发生DKA及酮症的病例，但非常少见。临床报道的病例中，部分病例为T1DM，多数患者存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理的压力等诱因，部分联合使用胰岛素的患者胰岛素减量过快。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂主要通过减少肾脏对葡萄糖的重吸收、增加葡萄精排泄而降低血糖水平。SGLT-2抑制剂可使HbA1c降低0.5%~1.0%，同时减轻患者体重(平均减少1.8kg)。由于SGLT-2抑制剂增加尿糖排出，会导致代偿性的食欲旺盛，故其减重作用需要配合控制饮食或其他类似手段。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "代偿性的食欲旺盛", "subject_type": "不良反应", "object": {"@value": "SGLT-2抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.胰岛β细胞功能已明显衰竭的2型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能已明显衰竭", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.探索中药和中西医结合治疗糖尿病肾病：中药抽提物(如大黄酸、雷公藤甲素等)及中成药(如复方血栓通胶囊、金水宝等)对降低尿白蛋白及改善肾功能有一定的疗效，目前正在积累更多循证医学的依据。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷公藤甲素", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "大黄酸", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "复方血栓通胶囊", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "金水宝", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "改变生活方式包括饮食治疗、运动、戒酒、戒烟、控制体重，有利于减缓糖尿病肾病进展，保护肾功能。近期研究证明控制多种危险因素(降糖、降脂、降压并注意生活干预后)糖尿病肾病发展至肾功能衰竭的比例明显下降，生存率明显增加。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "改变生活方式", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒酒", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "控制体重", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.ACS：若血糖>10.0mmol/L，可使用以胰岛素为基础的治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免低血糖发生。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "生活方式干预应当作为所有T2DM合并肥胖治疗的基础性措施并长期坚持。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "人胰岛素经济、安全、有效，在2型糖尿病治疗中发挥重要的作用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "人胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病相关临床指标评估：如血糖、糖化血红蛋白、血压、血脂等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6. X线：早期急性关节炎可见软组织肿胀，反复发作后可出现关节软骨缘破坏、关节面不规则、关节间隙狭窄；痛风石沉积者可见骨质呈凿孔样缺损，边缘锐利，缺损呈半圆形或连续弧形，骨质边缘可有骨质增生反应。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "软组织", "subject_type": "患病部位", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节软骨缘", "subject_type": "患病部位", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节面", "subject_type": "患病部位", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "软组织肿胀", "subject_type": "临床表现", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "关节软骨缘破坏", "subject_type": "临床表现", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "关节面不规则", "subject_type": "临床表现", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "关节间隙狭窄", "subject_type": "临床表现", "object": {"@value": "早期急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "骨质边缘可有骨质增生反应", "subject_type": "临床表现", "object": {"@value": "痛风石沉积"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "缺损呈半圆形或连续弧形", "subject_type": "临床表现", "object": {"@value": "痛风石沉积"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "骨质呈凿孔样缺损，边缘锐利", "subject_type": "临床表现", "object": {"@value": "痛风石沉积"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)大血管并发症：血糖波动与糖尿病患者冠心病严重程度显著相关，其作用独立于血糖水平本身，平均血糖波动幅度(mean amplitude of glucose excursions，MAGE)与患者急性心肌梗死事件再发显著相关。荟萃分析亦提示，血糖波动与心血管疾病的发生风险显著相关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "急性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)降糖药物：各种降糖药物均能不同程度地降低FPG和PPG，以降低PPG为主的口服降糖药包括α-糖苷酶抑制剂、短效磺脲类促泌剂、格列奈类促泌剂、二肽基肽酶一4(DPP-4)抑制剂；以降低PPG为主的注射制剂包括短效胰岛素及速效胰岛素似物、短效胰升血糖素样肽-1(GLP-1)受体激动剂。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "α-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "短效磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "格列奈类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二肽基肽酶一4(DPP-4)抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "效胰岛素似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "短效胰升血糖素样肽-1(GLP-1)受体激动剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "肝功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "肝功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肝功能检查", "subject_type": "检查方法", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.GDM患者与糖尿病合并妊娠(PGDM)患者：妊娠期间高血糖会增加围生期母婴发生不良临床结局的风险，故相比一般糖尿病患者血糖控制应更加严格。GDM血糖值控制在餐前≤5.3mmol/L，1hPG及2 hPG分别为≤7.8或6.7mmol/L，HbA1c<5.5%；PGDM妊娠期餐前、夜间血糖及FPG宜控制在≤5.6mmol/L，餐后峰值血糖5.6~7.1mmol/L，HbA1c<6.0%。GDM与PGDM患者，通过饮食治疗血糖不能得到满意控制时，需起始胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "1hPG", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "夜间血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后峰值血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "PGDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "PGDM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "常见原因包括：药物剂量、剂型或给药时间，甚至治疗方案需要调整，均可能与低血糖相关；过强的身体运动时肌肉等外周组织对葡萄糖摄取和利用增加，而消耗血糖；未正常进食，或隔夜禁食时间偏长等，导致食物来源的外源性葡萄糖摄入减少或延迟所致；因肾功能不全等疾病，使体内胰岛素或胰岛素促泌剂清除能力下降，血中胰岛素或胰岛素促泌剂浓度过高，血糖被过度降低。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "但在日本和我国台湾中小学生开展大样本尿糖筛查已有多年，结果表明其仍有一定效益。目前认为在超重并有2项或2项以上其他糖尿病危险因素(一级或二级亲属中有2型糖尿病病史，胰岛素抵抗相关临床状态，母亲妊娠期糖尿病史)的儿童和青少年，应考虑筛查2型糖尿病和糖尿病前期。可使用空腹血糖、糖耐量试验2h血糖或HbA1c筛查糖尿病前期。应该通过饮食控制和运动降低糖尿病前期的糖尿病发生风险，同时每年进行检测。对于糖尿病前期的人群，需同时筛查并治疗可改变的心血管疾病危险因素，包括血脂，血压的检测和控制。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "超重", "subject_type": "患病病因", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "胰岛素抵抗", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖耐量试验", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2h血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压的检测", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "虽然既往流行病学调查中使用的超重、肥胖的诊断标准略有不同，但仍然可在一定程度上反映其高患病率，T2DM合并肥胖的管理形势非常严峻。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.非酒精性脂肪肝病(NAFLD)：2型糖尿病患儿25%~50%合并有NAFLD，故糖尿病一经诊断即需对此相应评估，包括肝脏B超或磁共振肝脏脂肪定量等，以后每年1次。对于有胰岛素抵抗的患儿，控制体重及口服二甲双胍均能降低肝酶，改善NAFLD。护肝药虽可用于肝功能损伤，但对于2型糖尿病合并NAFLD的青少年，最佳方法还是改善胰岛素抵抗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪肝病(NAFLD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肝脏B超", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "磁共振肝脏脂肪定量", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "五、妊娠期高血糖", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.早治疗：包括早开始治疗性生活方式干预(TLC)、及时开始降血糖药物治疗和适时开始胰岛素治疗。检查发现FPG>5.6mmol/L、2hPG或随机血糖>7.8mmol/L或HbA1c>6.0%，是开始通过TLC防治糖尿病的警示点(IV)。如经过3个月TLC，HbA1c仍>6.5%需考虑开始非胰岛素促泌剂类口服降糖药物干预(IV)。我国的大庆研究、芬兰糖尿病预防研究(DPS)和美国的糖尿病预防研究(DPP)显示，单纯TLC可以使糖尿病的发病率减少50%~58%，阿卡波糖和二甲双胍药物干预研究分别降低糖尿病发病率88%和77%，疗效优于单纯TLC(A)。老年糖尿病患者在饮食和运动治疗的基础上HbA1c>7.0%，需要考虑单药或联合口服降糖药物治疗，根据患者胰岛素水平、肥胖程度及血糖波动的特点，将HbA1c控制到7.0%以内(B)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG或随机血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "TLC", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "非胰岛素促泌剂类口服降糖药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "TLC", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "TLC", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食和运动治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.胰岛素及其他注射药物管理：胰岛素是目前糖尿病治疗最有效的药物之一，但据研究显示，我国即使在已经使用胰岛素的患者中.血糖达标率也只有37%，而患者对胰岛素注射技术掌握不到位可能是重要原因之一。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "诊断依据：(1)符合糖尿病诊断；(2)具有下肢缺血的临床表现；(3)辅助检查提示下肢血管病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类)：抑制细胞内胆固醇合成早期阶段的限速酶即HMG-CoA还原酶，造成细胞内游离胆固醇减少，并通过反馈性上调细胞表面LDL受体的表达，因而使细胞LDL-C受体数目增多及活性增强，加速了循环极低密度脂蛋白(VLDL)残粒[或中间密度脂蛋白(IDL)]和LDL-C的清除。轻至中度肾功能患者无需调整辛伐他汀、氟伐他汀等他汀类的药物用量，但在重度肾功能不全(如Ccr<30ml/min)时需减量或禁用。肾脏疾病不影响阿托伐他汀的血浆浓度和其降低LDL-C的效果，故肾功能不全患者均无需调整其用药剂量，同时，由于阿托伐他汀与血浆蛋白的广泛结合，血液透析并不能显著提高其清除率，但目前由于缺乏其在透析患者中的用药经验，故仍需谨慎用药。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆蛋白", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氟伐他汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Ccr", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆浓度", "subject_type": "检查指标", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国T2DM合并CKD患者是一个数量庞大且不容忽视的人群，患者预后较仅有T2DM或仅有CKD患者更差。在临床实践中，应重视T2DM合并CKD患者口服降糖药的正确选择和规范使用。一旦GFR<60ml/(min·1.73m2)，大多数口服降糖药的药代动力学特征将会改变，低血糖及其他不良反应风险显著增加。遵循指南可使降糖达标率显著升高，低血糖风险显著降低，且入院率和治疗费用均显著下降。因而，对于T2DM合并CKD患者的口服降糖药治疗，尤应重视指南推荐和规范应用。在临床实践中，T2DM合并CKD患者应监测血糖，依据患者的肾功能分期选择合适降糖药并调整剂量，以保证有效控制血糖的同时能够最大程度减少低血糖风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.微量营养素：肥胖与某些微量营养素的代谢异常相关，尤其是钙、铁、锌、维生素A、维生素D及叶酸的缺乏。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "微量营养素的代谢异常", "subject_type": "发病机制", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "维生素D及叶酸的缺乏", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足是导致我国糖尿病患者致残、致死的严重慢性并发症之一，其发病率高，治疗困难，花费巨大目前我国主要是参考国际足病工作者与美国糖尿病足病学组制定的指南。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "注意事项：①别嘌醇的严重不良反应与所用剂量相关，当使用最小有效剂量能够使血尿酸达标时，尽量不增加剂量。②控制急性痛风发作时，建议同时应用秋水仙碱或其他消炎药，尤其是在治疗的早期。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "秋水仙碱", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.微循环扩张剂：(1)胰激肽原酶肠溶片(怡开)：有改善微循环作用。主要用于微循环障碍性疾病，如糖尿病引起的肾病、周围神经病、视网膜病。脑出血及其他出血性疾病的急性期禁用。(2)羟苯磺酸钙(导升明)可用于糖尿病性微血管病变：视网膜病及肾小球硬化症(基·威氏综合征)，严重肾功能不全需透析的患者应减量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑出血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙(导升明)", "subject_type": "药品名称", "object": {"@value": "糖尿病性微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病性微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球硬化症(基·威氏综合征)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在应用表1指标时要注意，临床上1型糖尿病和2型糖尿病有时仍然较难鉴别，究其原因包括：(1)肥胖多为2型糖尿病的特点，但儿童肥胖发病率增加，导致新诊断的1型糖尿病也有30%合并肥胖。(2)2型糖尿病诊断时如在急性期，不少也可合并代谢紊乱包括酮症或酮症酸中毒。(3)在一些地区和人群中，糖尿病发病率可高达15%，导致阳性家族史常见。(4)胰岛素及C肽释放试验的局限性。由于各种原因，在1型糖尿病和2型糖尿病特定病程中胰岛素和C肽水平可有部分重叠。如蜜月期时，1型糖尿病的C肽水平可处于正常范围之内，而急性高血糖时，由于高血糖对胰岛细胞的毒性作用，也可导致2型糖尿病的C肽水平相对较低，如果临床病情稳定后数月C肽水平仍然低下，则倾向于诊断1型糖尿病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着社会经济的发展，糖尿病患病率逐渐增加，已成为严重的世界性问题。糖尿病特别是其慢性并发症影响患者的生活质量，甚至威胁患者的生命，给社会、家庭以及患者带来沉重的经济负担。中国的流行病学调查显示，中国20岁以上人群2型糖尿病患病率达9.7%；且近2/3的患者HbA1c得不到有效控制(HbA1c≤7%)；60.7%的患者因未被诊断而无法及早进行有效的治疗和指导。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，体重不是使用二甲双胍治疗与否的决定因素(Ⅰ级)。无论对于超重患者还是体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.2 DPP-4抑制剂联合噻唑烷二酮类噻唑烷二酮类是选择性PPAR-γ(peroxisome proliferator-activated receptor-gamma)受体激动剂，主要通过增加糖尿病患者外周组织对胰岛素的敏感性来改善胰岛素抵抗。DPP-4抑制剂与噻唑烷二酮类药物联合直接针对2型糖尿病最重要的两个发病因素，部分基础研究显示两者联合治疗能够增加胰岛β细胞再生，联合治疗可能会提供更好和更持久的血糖控制和β细胞功能的保护。研究显示不同的DPP-4抑制剂与TZD类药物的联用均可降低空腹和餐后血糖，24周联合治疗HbA1c水平与对照组相比可降低约1.0%，HbA1c达标率更高。FDA已经批准了西格列汀、利格列汀、阿格列汀以及沙格列汀与TZD类药物联合应用，但是目前中国尚未批准任何DPP-4抑制剂与TZD类药物的联用。对于二甲双胍不能耐受或严重胰岛素抵抗的患者，TZD和DPP-4抑制剂的联合治疗也是一种可能的选择。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "选择性PPAR-γ(peroxisome proliferator-activated receptor-gamma)受体激动剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "胰岛素抵抗"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "不能耐受", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "TZD", "subject_type": "药品名称", "object": {"@value": "胰岛素抵抗"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "胰岛素抵抗"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者血糖控制目标应该遵循个体化原则，即对血糖控制的风险(risk)与获益(benefit)、成本(cost)与效益(effectiveness)和可行性(feasibility)方面进行科学评估，寻找较为合理的平衡，这一点已是专家共识。在我国，多数糖尿病患者居住在县以下及农村地区，经济、受教育程度、医疗保障及医疗水平等诸多影响血糖控制的因素差别极大，地域差别较强，因此临床医生在设定糖尿病血糖控制目标时除考虑病理生理因素即病情外，还必须考虑社会因素，社会因素的重要性在某些特定患者甚至超过病情。比如自我血糖监测(SMBG)在我国开展不普遍，因此防范严重低血糖的发生必须放在首位，HbA1c目标的制定应统筹考虑安全性、可行性和科学性。我们不主张笼统推荐成人2型糖尿病的HbA1c控制目标，而是根据病情分层和社会因素的差异建议相对合理的HbA1c值，力争做到安全达标。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自我血糖监测(SMBG)", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "手术治疗：如尿酸结石造成尿路梗阻、严重感染或肾功能受损时采用手术治疗，包括开放手术、经皮肾镜手术及输尿管软镜手术。大于2.0cm肾结石、复杂性肾结石建议采用经皮肾镜。躯体严重畸形、过度肥胖等难以建立经皮肾痛道者为手术禁忌；输尿管软镜手术可用于体外冲击波效果不佳，直径小于2.0cm的结石。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "尿酸结石", "subject_type": "患病病因", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿酸结石", "subject_type": "患病病因", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿酸结石", "subject_type": "患病病因", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "尿路", "subject_type": "患病部位", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "复杂性肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "输尿管软镜手术", "subject_type": "临床手术", "object": {"@value": "结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题11：GLP-1RA联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.二甲双胍的胃肠道反应与剂量的相关性，以及处理措施：二甲双胍引起的胃肠道反应多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。一项多中心、双盲、安慰剂对照研究显示，二甲双胍(1000mg/d)起始治疗，其胃肠道反应发生率为24%，增至2500mg/d时胃肠道反应发生率与1000mg/d比较，差异无统计学意义(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "b.维格列汀均在中度或重度肾功能不全患者或需要接受血液透析治疗的终末期肾脏疾病(ESRD)患者中的应用经验有限，因此不推荐此类者使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾脏疾病(ESRD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "终末期肾脏疾病(ESRD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "终末期肾脏疾病(ESRD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "据国际糖尿病联盟(IDF)2013年公布的数据，全球有510万人死于糖尿病相关疾病，占总死亡人数的8.39%。我国近年来研究报道糖尿病的病死率明显增加，10、20、30年间分别增长1.12倍(北京1991—2000年)、4.15倍(上海市徐汇区1986—2005年)和11.61倍(武汉1975—2006年)，糖尿病可致早亡，人均死亡损失寿命年为5.4~6.8人年，均为女性高于男性，60岁以上人群明显增加。主要死亡原因在欧美国家是心血管疾病，国内报道是心、脑血管疾病，其次为恶性肿瘤、肺部感染、肾衰竭。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心、脑血管", "subject_type": "患病部位", "object": {"@value": "心、脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺部", "subject_type": "患病部位", "object": {"@value": "肺部感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "l-II级", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "III一IV级", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "当病史和体检已经能够明确周围神经病变及其类型时，神经电生理检查并非必需。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "神经电生理检查", "subject_type": "检查方法", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、T2DM患者的血脂异常特点及流行病学", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍的降糖作用机制：二甲双胍治疗糖尿病的作用机制包括(1)通过直接抑制肝脏的糖异生降低FPG；(2)通过提高外周组织(肌肉、脂肪)对葡萄糖的摄取和利用，降低PPG；(3)减少小肠内葡萄糖吸收；(4)通过抑制线粒体复合物Ⅰ和线粒体氧化磷酸化，减少ATP合成，激活AMPK，促进脂肪酸进入线粒体进行脂肪酸β氧化，减少脂肪合成，从而减轻IR；(5)改善IS，提高胰岛β细胞对血糖的应答；(6)升高GLP-1水平。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GLP-1", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GFR低于15ml·min-1·1.73m-2的糖尿病肾病患者在条件允许的情况下可选择肾脏替代治疗，包括血液透析、腹膜透析和肾脏移植等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "腹膜透析", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "肾脏移植", "subject_type": "临床手术", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)若低预混胰岛素每日2次治疗，HbA1c≥7.0%，早餐后血糖<10.0mmol/L，可考虑调整为低预混胰岛素类似物每日3次；若早餐后血糖≥10.0mmol/L的患者，则可考虑调整为中预混胰岛素类似物3次治疗；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500~2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每日用量达到1000豪克", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "本共识特别强调在HUA以及痛风患者治疗过程中必须做到多学科联合治疗。(1)应关注高危人群：高龄男性、肥胖、一级亲属中有痛风史者、患有心血管疾病、肾脏疾病人群，应定期监测血清血尿酸(SUA)浓度。同时尽量避免各种危险因素因素；饮食因素、其他疾病治疗过程中的药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇均可抑制尿酸在肾小管的排泄导致HUA。同时在高危人群中强调非药物治疗，包括正确生活方式指导。共时指出，健康饮食、戒烟限酒、坚持运动和控制体质量、大量饮水适当碱化尿液等生活方式改变可预防HUA，这些需要专科医师体验中心、营养师、慢病管理团队等多学科联合进行。(2)确诊的HUA或痛风患者应积极筛查并发症或合并症，及时制定多学科联合治疗方案：肾病患者须避免使用损害肾脏药物并定期监测肾功能；肾石症患者须碱化尿液，必要时给予溶石或手术治疗；合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物，如对于高胆固醇血症或动脉粥样硬化合并HUA的患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先选用非诺贝特；高血压合并HUA患者降压药物优选氯沙坦、二氢吡啶类钙通道阻滞剂等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "饮食因素", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "抑制尿酸在肾小管的排泄", "subject_type": "发病机制", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "健康饮食", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟限酒", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "坚持运动", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "控制体质量", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "大量饮水", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "监测肾功能", "subject_type": "检查方法", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "溶石", "subject_type": "非药治疗", "object": {"@value": "肾石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "高胆固醇血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二氢吡啶类钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二氢吡啶类钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "针对高尿酸血症不同治疗方法的有效性和安全性比较的研究分析显示，与其他药物相比，非布司他具有更好的疗效和安全性。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐19：在临床中，T2DM患者一些常用的药物会影响患者的血脂水平，临床医师在处方药物时应该考虑到这些潜在的药物作用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "b.维格列汀不推荐用于开始给药前血清谷丙转氨酵或谷草转氨酶大于正常上限3倍的患者；罕见有肝功能障碍(包括肝炎)报告，需要进行定期检测肝酶；", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肝功能障碍", "subject_type": "不良反应", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝炎", "subject_type": "不良反应", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1987年Mogensen建议，根据糖尿病肾病的病理生理特点和演变过程，将1型糖尿病患者的糖尿病肾病分为5期。I期：急性肾小球高滤过期，肾小球入球小动脉扩张，肾小球内压增加，GFR升高，伴或不伴肾体积增大；II期：正常白蛋白尿期，UAE正常(<20μg/min或<30mg/24h)(如休息时)，或呈间歇性微量白蛋白尿(如运动后、应激状态)，病理检查可发现肾小球基底膜轻度增厚；Ⅲ期：早期糖尿病肾病期(UAE 20~200μg/min或30~300mg/24h)，以持续性微量白蛋白尿为标志，病理检查肾小球基底膜(GBM)增厚及系膜进一步增宽；IV期：临床(显性)糖尿病肾病期，进展性显性白蛋白尿，部分可进展为肾病综合征，病理检查肾小球病变更重，如肾小球硬化，灶性肾小管萎缩及间质纤维化；V期：肾衰竭期。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "UAE", "subject_type": "检查指标", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "UAE", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "肾小球硬化", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "灶性肾小管萎缩", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "间质纤维化", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "胃", "subject_type": "患病部位", "object": {"@value": "胃肠道疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肠道", "subject_type": "患病部位", "object": {"@value": "胃肠道疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "附录3 各项糖尿病微血管并发症检查方法DR：眼底检查或眼底照相。DKD：指导患者留取血、尿标本。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底照相", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.年龄在18~60岁，一般状况较好，手术风险较低，经生活方式干预和各种药物治疗难以控制的2型糖尿病患者(HbA1c>7.0%)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病的基础治疗包括教育和管理、饮食和运动两方面。缺乏糖尿病防治知识是血糖控制差的最主要原因。重视老年患者的教育和管理是提高糖尿病治疗水平的重要举措。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "基础治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "教育和管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食和运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "教育和管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.糖尿病肾病与慢性肾衰竭：老年糖尿病肾损伤常为多因素致病。遗传因素、高血压、高血糖、肥胖、高尿酸及肾毒性药物是老年慢性肾病进展的主要影响因素，糖尿病所致肾损伤仅占1/3(D)。糖尿病肾病治疗原则：严格饮食管理(摄入优质蛋白，<0.6g·kg-1·d-1)，减轻肾脏负担(I)。治疗措施包括尽早应用肾素血管紧张素系统(RAS)抑制剂、严格控制血糖、肥胖者减轻体重、控制血压(<130/80mmHg)、控制高尿酸血症及改善肾脏微循环等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "遗传因素", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血压", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肥胖", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高尿酸", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肾毒性药物", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "肾素血管紧张素系统(RAS)抑制剂", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(6)口服降糖药物，包括二肽基肽酶4(DPP-4)抑制剂和GLP-1受体激动剂在住院高血糖患者的使用证据较少。如果患者的临床状况比较稳定、进食规律并且没有使用这些药物的禁忌证，则在入院后可以考虑维续应用其入院前已经使用的口服降糖药物或GLP-1受体激动剂。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二肽基肽酶4(DPP-4)抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二肽基肽酶4(DPP-4)抑制剂", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)持续封闭式负压吸引：可有效改善创面引流，加速坏死组织溶脱和肉芽组织增生，但需住院接受治疗。对糖尿病足创面应注意避免压力设置过高、避免因覆盖不当导致相邻足趾压迫缺血。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足趾压迫缺血", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)糖尿病周围神经病变的诊断 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)血管病变检查 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前，2型糖尿病及其并发症已经成为危害公众健康的主要疾病之一，控制血糖是延缓糖尿病进展及其并发症发生的重要措施之一。虽然HbA1c是评价血糖控制水平的公认指标，但应该控制的理想水平即目标值究竟是多少还存在争议。糖尿病控制与并发症试验(DCCT，1993)、熊本(Kumamoto，1995)、英国前瞻性糖尿病研究(UKPDS，1998)等高质量临床研究已经证实，对新诊断的糖尿病患者或病情较轻的患者进行严格的血糖控制会延缓糖尿病微血管病变的发生、发展，其后续研究DCCT-EDIC(2005)、UKPDS一80(2008)还证实早期有效控制血糖对大血管也有保护作用。这些研究终点的HbA1c控制在7.5%左右，那么年龄较大、糖尿病病程较长、部分已有心血管疾病(CVD)或伴CVD极高危因素的糖尿病人群进一步降低血糖，对CVD的影响将会如何?糖尿病患者心血管风险干预研究(ACCORD)、退伍军人糖尿病研究(VADT)和糖尿病与心血管疾病行动研究(ADVANCE)等对该类人群平均5年左右的干预，结果显示强化降糖治疗使HbA1c<6.5%，患者死亡风险和大血管事件发生并无进一步减少，ACCORD甚至表明控制HbA1c水平接近正常值(<6.4%)会增加这类患者死亡率。这些与理论或预期不一致结果产生的原因尚不确定，可能与人组人群差异、低血糖、体重增加、随访时间长短及评估方法等诸多因素有关，但过分苛求血糖正常化可能是主要原因之一。ACCORD、VADT数据分析提示对病程长、有低血糖史、有CVD或合并CVD极高危的患者，盲目地进行强化达标治疗，会明显增加低血糖和心血管事件发生。各权威组织推荐的血糖控制目标HbA1c的水平也不尽相同，美国糖尿病协会(ADA)认为一般情况下血糖控制目标值HbA1c<7%；国际糖尿病联盟(IDF)、美国内分泌医师协会/美国内分泌协会(AACE/ACE)、英国健康与临床优化研究所(NICE)、全球有效管理糖尿病合作组织(GPEDM)和加拿大糖尿病协会(CDA)则建议一般情况时HbA1c<6.5%；中华医学会糖尿病分会推荐的一般HbA1c目标值为<6.5%。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)格列奈类：格列奈类降糖药为非磺脲类胰岛素促泌剂，主要通过刺激早相胰岛素分泌而降低餐后血糖，具有吸收快、起效快和作用时间短的特点，可降低HbA1c0.5%~2.0%，其低血糖的风险和程度较磺脲类药物轻。格列奈类主要代表药物为那格列奈和瑞格列奈。那格列奈及其代谢产物83%经肾脏排泄，随着肾功能的降低，那格列奈的活性代谢产物水平增加，而瑞格列奈却未发现此现象。瑞格列奈及其代谢产物仅8%经肾脏排泄。瑞格列奈Ⅰ期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度CKD患者相比，血药浓度没有明显差别，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全T2DM患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损害)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损害程度无关。瑞格列奈用于CKD1~5期的患者无需调整剂量；如起始用药，应0.5mg起始。那格列奈用于CKD1~3a期患者时，无需调整剂量；3b~4期减量；5期禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类降糖药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "非磺脲类胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "正常、轻、中、重、极重肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "正常、轻、中、重、极重肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD1~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5mg", "subject_type": "用药剂量", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3a期", "subject_type": "分期分型", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b~4期", "subject_type": "分期分型", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "5期", "subject_type": "分期分型", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病是由于胰岛素抵抗，引起胰岛素分泌相对不足导致血糖升高，往往合并其他代谢异常，由于后期β细胞功能衰竭，最终也可导致胰岛素分泌绝对不足。除了高血糖外，还可表现出脂代谢异常，高血压，多囊卵巢综合征(PCOS)，脂肪肝等。2型糖尿病的胰岛素分泌随着疾病状态和病程的不同差异较大，可以是糖负荷高峰延迟，也可以是处于完全的低分泌状态。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌相对不足", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "后期β细胞功能衰竭", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌绝对不足", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "代谢异常", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "糖负荷高峰延迟", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "完全的低分泌状态", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "卵巢", "subject_type": "患病部位", "object": {"@value": "多囊卵巢综合征(PCOS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "脂肪肝"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尚无明确证据表明富含纤维的蔬菜的摄入对糖尿病肾病有益。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为进一步提高我国心血管专科医师对心血管疾病合并糖尿病患者的综合防治能力与水平，让工作在一线的临床医师能够充分了解心血管疾病患者的糖尿病筛查流程和诊断标准、常用口服降糖药物选择以及血糖控制目标值，中国医师协会心血管内科医师分会组织心内科、内分泌科以及肾内科等领域专家，共同制订此共识。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐4：对于血脂位于正常范围内的患者，如果无其他心血管风险。在T2DM治疗过程中每年至少要进行1次血脂谱的检测：如果伴有多重心血管风险因素，则在诊断T2DM后每3个月监测血脂谱1次。对于合井血脂谱异常的T2DM患者，则在起始生活方式干预和药物治疗，以及药物剂量调整期间每1~3个月监测1次血脂谱，此后则建议每3~12个月监测1次血脂谱。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病病程长(>15年)、有“无感知”低血糖病史、存在肝肾功能不全或全天血糖波动较大并反复出现低血糖症状的患者给予胰岛素促泌剂治疗时，应选择格列奈类促泌剂或低血糖风险较低的磺脲类促泌剂(1b级，5级)；一般应小剂量开始使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列奈类促泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂治", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)糖皮质激素：主要用于严重急性痛风发作伴有较重全身症状，秋水仙碱、NSAIDs治疗无效或使用受限的患者以及肾功能不全患者。全身给药时，口服泼尼松0.5mg·kg-1.d-1连续用药5～10d停药，或者0.5mg·kg-1d-1用药2～5d后逐渐减量，总疗程7～10d。不宜口服用药时，可考虑静脉使用糖皮质激素。使用糖皮质激素应注意预防和治疗高血压、糖尿病、水钠潴留、感染等不良反应，避免使用长效制剂。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "急性痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5mg·kg-1.d-1", "subject_type": "用药剂量", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5mg·kg-1d-1", "subject_type": "用药剂量", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5～10d", "subject_type": "持续时间", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2～5d", "subject_type": "持续时间", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "7～10d", "subject_type": "持续时间", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高血压", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "糖尿病", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "水钠潴留", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "感染", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识指出对HUA和痛风患者，在尿酸测定之后，必须要针对患者的具体情况进行评估，不同的尿酸水平在不同的人群对器官的损害水平是不同的。在治疗上遵循个体化、分层、达标、长程管理的原则，逐步调整剂量以避免短期内血尿酸水平波动过大诱发痛风急性发作。共识指出应该根据患者SUA水平的不同和是否合并心血管危险因素或心血管及代谢性疾病的状态给予积极的分层治疗；在今后的临床实践中灵活应用，可有效预防和降低HUA对机体各脏器的危害。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "心血管及代谢性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管及代谢性疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.针对65岁以上老年患者如何使用二甲双胍：((2013年IDF老年糖尿病指南》和《中国老糖尿病诊疗措施专家共识》都推荐二甲双胍为一线首选用药，并没有限制二甲双胍的具体使用年龄。老年糖尿病患者合理应用二甲双胍可以达到良好的降糖效果，且较少的低血糖风险对老年患者也有一定益处，但需要定期监测肾功能(3~6个月检查1次)。80岁以上患者[eGFR<45ml/(min·1.73m2)除外]如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍然可取得良好效果。因此，年龄并非二甲双胍治疗的禁忌，但需要定期监测肾功能。老年患者的eGFR 45~59ml/(min·1.73m2)者，应该减少剂量；如eGFR<45ml/(min·1.73m2)，则不能使用。适合我国CKD患者的eGFR评估公式为：eGFR=175XScr-1.234(mg/dl)×年龄-0.179(女性X0.79)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素仍是迄今为止最强有效的降糖药物，胰岛素的增重效应呈剂量依赖性和个体差异性，但不同胰岛素种类在增重方面有所差异，如基础胰岛素类似物-地特胰岛素具有体重增加较少的优势。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "增重", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增重", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "目前，国内临床使用的基础胰岛素主要包括中效胰岛素(NPH，中性鱼精蛋白锌胰岛素) 、长效胰岛素(PZI，精蛋白锌胰岛素) 和长效人胰岛素类似物 (甘精胰岛素，地特胰岛素等) ，详见表5。NPH具有明显峰值，变异性较大，低血糖发生风险相对高，但价格较低。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "NPH"}, "object_type": {"@value": "药品名称"}}]}
{"text": "临床问题1：DPP-4i是否可作为2型糖尿病患者的一线治疗选择之一?", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)持续皮下胰岛素输注", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
